ArticleFrontiers in pharmacology2017
Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse.
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- Adelmidrol to fight upper airways inflammation in children: a pilot case control study to safety and efficacy.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Trial
- The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis-A Double-Blind Placebo-Controlled Trial.Nutrients · 2023Trial
- Integrative analysis of the intestinal metabolome of childhood asthma.The Journal of allergy and clinical immunology · 2019Trial
- Palmitoylethanolamide (PEA) Induces an Increase in Spleen Regulatory T Cells, Reduces CD8Immunology · 2025Article
- Beyond the pill: incrimination of nuclear factor-kappa B and their targeted phytomedicine for pulmonary fibrosis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Nutraceutical formulation based on a synergic combination of melatonin and palmitoylethanolamide for the management of allergic events.Frontiers in nutrition · 2024Article
- Beneficial Effects ofInternational journal of molecular sciences · 2023Article
- Online breath analysis with SESI/HRMS for metabolic signatures in children with allergic asthma.Frontiers in molecular biosciences · 2023Article
- Discovery and Optimization of Indoline-Based Compounds as Dual 5-LOX/sEH Inhibitors:Journal of medicinal chemistry · 2022Article
- Palmitoylethanolamide and Related ALIAmides for Small Animal Health: State of the Art.Biomolecules · 2022Review
- Lack of Ecto-5'-Nucleotidase Protects Sensitized Mice against Allergen Challenge.Biomolecules · 2022Article
- Molecular and Biochemical Mechanism of Cannabidiol in the Management of the Inflammatory and Oxidative Processes Associated with Endometriosis.International journal of molecular sciences · 2022Article
- Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans.Biomolecules · 2022Review
- Effects of UltramicronizedPharmaceutics · 2022Article
- The Hydroalcoholic Extract ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Peitu Shengjin Recipe Attenuates Airway Inflammation via the TLR4/NF-kB Signaling Pathway on Chronic Obstructive Pulmonary Disease.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Management of Acute Lung Injury: Palmitoylethanolamide as a New Approach.International journal of molecular sciences · 2021Article
- Palmitoylethanolamide: A Natural Compound for Health Management.International journal of molecular sciences · 2021Review
- Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients.Pharmaceuticals (Basel, Switzerland) · 2021Review
- GPR119 and GPR55 as Receptors for Fatty Acid Ethanolamides, Oleoylethanolamide and Palmitoylethanolamide.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One important risk factor for the development of asthma is allergen sensitization. Recent increasing evidence suggests a prominent role of mast cells in asthma pathophysiology. Since Palmitoylethanolamide (PEA), an endogenous lipid mediator chemically related to - and co-released with- the endocannabinoid anandamide, behaves as a local autacoid down-regulator of mast cell activation and inflammation, we explored the possible contribution of PEA in allergic sensitization, by using ovalbumin (OVA) as sensitizing agent in the mouse. PEA levels were dramatically reduced in the bronchi of OVA-treated animals. This effect was coupled to a significant up-regulation of CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.